Date:    4/6/99  1:24 PM

Subject: S7-5-99

Attn:  Jonathan G. Katz
     
As the President & CEO of Life Medical Sciences, Inc.(CHAI), I have recently 
had to suffer through negative effects on the price and trading volume for our 
common stock associated with it being delisted from the NASDAQ National Market 
to the OTC Bulletin Board.  Fortunately, this has been tempered by the 
continued involvement of the market makers who previously followed and traded 
our stock.  As a reporting company and one which has drawn more attention from 
the NASDAQ recently than we deserved, we should not have to further suffer the 
inevitable negative impact which will result from the proposed rule changes. 
As proposed, these rule changes will result in the loss of support of our 
market makers and thus further jeopradize the marketability of our stock. 
Legitimate microcap companies such as ours cannot survive without access to 
the capital markets on reasonable and visibility of our stock through the 
market makers.
     
I ask you to please reconsider these changes.
     
Sincerely yours,
     
Robert P. Hickey